Merck & Co. has unwrapped a fresh set of clinical data on sotatercept, providing further evidence of the safety and efficacy of the cardiovascular drug candidate ahead of a FDA ruling on whether to approve the jewel of the $11.5 billion Acceleron Pharma buyout.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,